Intravesical Liposome Treatment for Interstitial Cystitis

Information

  • Research Project
  • 7162402
  • ApplicationId
    7162402
  • Core Project Number
    R43DK074286
  • Full Project Number
    1R43DK074286-01A1
  • Serial Number
    74286
  • FOA Number
    PA-06-06
  • Sub Project Id
  • Project Start Date
    9/15/2006 - 18 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    NAYFIELD, SUSAN G.
  • Budget Start Date
    9/15/2006 - 18 years ago
  • Budget End Date
    8/31/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/13/2006 - 18 years ago

Intravesical Liposome Treatment for Interstitial Cystitis

[unreadable] DESCRIPTION (provided by applicant): Project Summary/Abstract: Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain. Presently, there is limited medical therapy for IC and new and effective treatment is a major unmet medical need. Lipella Pharmaceuticals Inc. intends to be the leading company specializing in the use of intravesical liposome technology to treat IC. We have developed a method of formulating highly specific liposomes for intravesical installation. The technology is licensed from inventions and research by Drs. Leaf Huang and Michael Chancellor at the University of Pittsburgh. Based on their research that a liposome itself can provide a soothing effect to an irritated bladder, Lipella Pharmaceuticals expects that intravesical liposome formulations can present an improved activity in patients with IC. Lipella Pharmaceuticals currently has a number of liposome compositions that demonstrate efficacy in treating induced bladder irritation in a rat model. The most promising compound, LPA-08, is the subject of this grant proposal. The specific composition of LPA-08, and initial efficacy results in rats, indicate that LPA-08 shows promise as a safe and effective therapy for bladder irritation. The effort proposed here would, in part, contribute to pre-clinical data collection prior to filing an FDA Investigational New Drug (IND) application, a regulatory requirement prior to administering LPA-08 in man. Such efforts include exploring the pharmacology of LPA-08, as well as its distribution post-installation. Project Narrative: We propose key preclinical experiments in an animal model to validate follow-on inves ment for clinical development of a novel treatment for painful bladder syndrome, an in-curable chronic illness involving pain, urinary urgency, loss of sleep, depression and anxiety in approximately 500,000 women domestically. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99617
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:99617\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LIPELLA PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    187190850
  • Organization City
    PITTSBURGH
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    152171919
  • Organization District
    UNITED STATES